1. Sigmund Freud Privatuniversität
  2. Publikationsdatenbank

Einfache Stichwortsuche: Stichwort/Text (mindestens 3 Zeichen)
Erweiterte Stichwortsuche:
1. Stichwort1/Text1 AND Stichwort2/Text2 (= Suchergebnis muss beide Stichwörter/Texte enthalten! 1 und 2!)
2. Stichwort1/Text1 OR Stichwort2/Text2 (= Suchergebnis muss entweder 1 oder 2 enthalten)

Zurücksetzen
2020
Ofenheimer, A., Breyer-Kohansal, R., Hartl, S., Burghuber, O. C., Krach, F., Schrott, A., Wouters, E. F. M., Franssen, F. M. E., & Breyer, M. (2020). Reference values of body composition parameters and visceral adipose tissue (VAT) by DXA in adults aged 18–81 years—results from the LEAD cohort. European Journal of Clinical Nutrition, 74(8), 1181-1191. doi: https://doi.org/10.1038/s41430-020-0596-5 (IF: 3.114)
Perkmann, T., Perkmann-Nagele, N., Breyer, M. K., Breyer-Kohansal, R., Burghuber, O. C., Hartl, S., Aletaha, D., Sieghart, D., Quehenberger, P., Marculescu, R., Mucher, P., Strassl, R., Wagner, O. F., Binder, C. J., & Haslacher, H. (2020). Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on Specificity. Clin Chem, 66(11), 1405-1413. doi: 10.1093/clinchem/hvaa198
2019
Breyer-Kohansal, R., Hartl, S., Breyer, M., Schrott, A., Studnicka, M., Neunhäuserer, D., Fülöp, G., & Burghuber, O. C. (2019). The European COPD audit : Adherence to guidelines, readmission risk and hospital care for acute exacerbations in Austria. Wien Klin Wochenschr., 131(5-6), 97-103. doi: 10.1007/s00508-019-1441-5
Buder, A., Setinek, U., Hochmaier, M. J., Schwab, S., Kirchbacher, K., Keck, A., Burghuber, O. C., Pirker, R., & Filipits, M. (2019). EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR. Target Oncol., 14(2), 197-203. doi: 10.1007/s11523-019-00623-x
Hochmaier, M. J., Buder, A., Schwab, S., Burghuber, O. C., Prosch, H., Hilbe, W., Cseh, A., Fritz, R., & Filipits, M. (2019). Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib. Target Oncol., 14(1), 75-83. doi: 10.1007/s11523-018-0612-z
2018
Breyer-Kohansal, R., Hartl, S., Burghuber, O. C., Urban, M., Schrott, A., Agusti, A., Sigsgaard, T., Vogelmeier, C., Wouters, E., Studnicka, M., & Breyer, M. (2018). The LEAD (Lung, Heart, Social, Body) Study: Objectives, Methodology, and External Validity of the Population-Based Cohort Study. Journal of Epidemiolgy, -(Epub), -. doi: 10.2188/jea.je20180039
Reiger, G., Zwick, R., Lamprecht, B., Kähler, C., Burghuber, O. C., & Valipour, A. (2018). Phenotypes of COPD in an Austrian population: National data from the POPE study. Wien Klin Wochenschr., 130(11-12), 382-389. doi: 10.1007/s00508-018-1347-7
2017
Eilenberg, W., Stojkovic, S., Kaider, A., Kozakowski, N., Domenig, C., Burghuber, C., Nanobachvili, J., Huber, K., Klinger, M., Neumayer, C., Huk, I., Wojta, J., & Demyanets, S. (2017). NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis. Clin Chem Lab Med, 2017, pii: /j/cclm.ahead-of-print/cclm-2017-0156/cclm-2017-0156.xml [Epub ahead of print]. doi: 10.1515/cclm-2017-0156
2015
Burghuber, O. C., Urban, M., & Hartl, S. (2015). Lungenkrankheiten im Zusammenhang mit dem Rauchen (außer Lungenkrebs und COPD). Atemwegs- und Lungenkrankheiten, 41, 1-8.